Mirum Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
MIRM Mirum Pharmaceuticals Inc
FCELB Fuelcell Energy Inc
UK Ucommune International Ltd
CRDF Cardiff Oncology Inc
TRNR Interactive Strength Inc
OMGA Omega Therapeutics Inc
ACST Acasti Pharma Inc
PYPD PolyPid Ltd
ACRX AcelRx Pharmaceuticals Inc
MI Nft Ltd

Health Care : Biotechnology | Small Cap Growth
Company profile

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. Its development pipeline consists of two clinical-stage product candidates, Livmarli and volixibat. Its product LIVMARLI (maralixibat) oral solution is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) three months of age and older in the United States and for the treatment of cholestatic pruritus in patients with ALGS two months of age and older in Europe. Its second product candidate, Volixibat is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The Company also offers bile acid product portfolio, which includes Cholbam (cholic acid) and Chenodal (chenodiol).

Day's Change
0.44 (1.45%)
B/A Size
Day's High
Day's Low

Today's volume of 215,550 shares is on pace to be much lighter than MIRM's 10-day average volume of 890,284 shares.


Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.